SonaCare Medical Announces Twelve Months Sales Results of Fifteen HIFU Devices

Fast paced sales growth sets a new company record and underscores the continued worldwide acceleration in demand for SonaCare’s unique HIFU platform technology.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

World-wide distribution of HIFU device sales

Charlotte, NC (PRWEB) August 27, 2014

NC. SonaCare Medical, LLC, the global leader in high intensity focused ultrasound (HIFU), announced record-setting sales of 15 HIFU devices over the past twelve months pointing to a steady worldwide surge in demand for the company’s ablation technology.

“It is truly exciting to see the results our team has achieved over the past year, especially since we are now heading into the Fall, which has historically been our most active sales period,” says Mike Klein, CEO of SonaCare Medical.

The majority of systems purchased have been outside of the United States where SonaCare sells the CE marked Sonablate® 500 transrectal prostate surgical HIFU device. Non-USA sales were well balanced between Brazil, Canada, the Dominican Republic, Italy, Mexico, Russia, Switzerland, and Uzbekistan.

SonaCare Medical generated additional sales within the United States where the company markets its 510(k) cleared Sonatherm® laparoscopic soft tissue HIFU surgical ablation system. Sonatherm sales were successfully completed at leading government medical institutions and university hospitals in Washington D.C, New York, California, and Texas.

“Achieving sales in multiple languages on four different continents over the past year is a testament to the growing worldwide demand for SonaCare’s unique HIFU platform. We are committed to working with each new customer to ensure that their SonaCare system is effectively integrated into their hospitals and surgical centers,” says Mike Klein.

For more information, please contact SonaCare Medical at +1 (888) 874-4384 or visit http://www.sonacaremedical.com.

About SonaCare Medical
SonaCare Medical, a privately held, venture-backed healthcare company, is a world leader in minimally-invasive high intensity focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing technologies for urological indications that offer precise and innovative procedures that can control cancer and reduce potential quality of life altering side effects. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures high intensity focused ultrasound (HIFU) medical devices, including the following: Sonablate® 450 which is investigational in the U.S. and being studied in a pivotal FDA clinical trial as a possible treatment for recurrent prostate cancer in patients treated previously with external beam radiation therapy; Sonablate® 500, which has CE Marking and is, or has been, approved for use to treat prostate cancer in more than 30 countries outside the U.S.; and Sonatherm® laparoscopic HIFU surgical ablation system which is 510(k) cleared in the U.S. The FDA has made no decision as to the safety or efficacy of Sonablate® 450 or 500. In the event Sonablate® 450 is approved by the FDA for use in the U.S., there is no assurance that instructions for use or the specifications of the device will be the same for treatment approved or authorized in other countries outside of the U.S. SonaCare Medical was founded in 2004 and is headquartered in Charlotte, N.C.
###


Contact